Protagonist Therapeutics, Inc (PTGX) Operating Margin
- Operating margin · 12 months: Value (m); Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | (m) | Operating income / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | 58.34M USD | Operating Income (Loss) |
| Revenue | (m) | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) | |
| Research and development | 175.16M USD | Research and Development Expense |
| Selling, general and administration | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $58.34M | (m) | (m) | $175.16M | (m) | (m) |
| 2026-03-31 | $-142.47M | (m) | (m) | $170.14M | (m) | (m) |
| 2025-12-31 | $-158.13M | (m) | (m) | $159.29M | (m) | (m) |
| 2025-09-30 | $19.01M | (m) | (m) | $147.84M | (m) | (m) |
| 2025-06-30 | $23.98M | (m) | (m) | $143.80M | (m) | (m) |
| 2025-03-31 | $27.22M | (m) | (m) | $140.29M | (m) | (m) |
| 2024-12-31 | $252.84M | (m) | (m) | $138.13M | (m) | (m) |
| 2024-09-30 | $149.11M | (m) | (m) | $132.12M | (m) | (m) |
| 2024-06-30 | $152.24M | (m) | (m) | $126.82M | (m) | (m) |
| 2024-03-31 | $148.68M | (m) | (m) | $126.48M | (m) | (m) |
| 2023-12-31 | $-93.65M | (m) | (m) | $120.16M | (m) | (m) |
| 2023-09-30 | $-153.22M | (m) | (m) | $121.15M | (m) | (m) |
| 2023-06-30 | $-147.19M | (m) | (m) | $115.88M | (m) | (m) |
| 2023-03-31 | $-146.28M | (m) | (m) | $117.31M | (m) | (m) |
| 2022-12-31 | $-131.37M | (m) | (m) | $126.22M | (m) | (m) |
| 2022-09-30 | $-131.87M | (m) | (m) | $134.70M | (m) | (m) |
| 2022-06-30 | $-133.50M | (m) | (m) | $146.26M | (m) | (m) |
| 2022-03-31 | $-122.94M | (m) | (m) | $138.08M | (m) | (m) |
| 2021-12-31 | $-125.84M | (m) | (m) | $126.01M | (m) | (m) |
| 2021-09-30 | $-107.66M | (m) | (m) | $107.12M | (m) | (m) |
| 2021-06-30 | $-81.50M | (m) | (m) | $86.16M | (m) | (m) |
| 2021-03-31 | $-68.84M | (m) | (m) | $79.98M | (m) | (m) |
| 2020-12-31 | $-64.52M | (m) | (m) | $74.51M | (m) | (m) |
| 2020-09-30 | $-62.98M | (m) | (m) | $70.93M | (m) | (m) |
| 2020-06-30 | $-72.38M | (m) | (m) | $72.23M | (m) | (m) |
| 2020-03-31 | $-85.57M | (m) | (m) | $71.33M | (m) | (m) |
| 2019-12-31 | $-80.52M | (m) | (m) | $65.00M | (m) | (m) |
| 2019-09-30 | $-78.63M | (m) | (m) | $63.34M | (m) | (m) |
| 2019-06-30 | $-70.86M | (m) | (m) | $58.19M | (m) | (m) |
| 2019-03-31 | $-48.69M | (m) | (m) | $56.57M | (m) | (m) |
| 2018-12-31 | $-42.27M | (m) | (m) | $59.50M | (m) | (m) |
| 2018-09-30 | $-30.37M | (m) | (m) | $56.97M | (m) | (m) |
| 2018-06-30 | $-25.96M | (m) | (m) | $55.99M | (m) | (m) |
| 2018-03-31 | $-31.85M | (m) | (m) | $50.27M | (m) | (m) |
| 2017-12-31 | $-37.90M | (m) | (m) | $46.18M | (m) | (m) |
| 2017-09-30 | $-45.78M | (m) | (m) | $43.28M | (m) | (m) |
| 2017-06-30 | $-47.94M | (m) | (m) | $37.67M | (m) | (m) |
| 2017-03-31 | $-39.90M | (m) | (m) | $31.36M | (m) | (m) |
| 2016-12-31 | $-32.67M | (m) | (m) | $25.70M | (m) | (m) |
| 2016-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-03-31 | $-19.14M | (m) | (m) | (m) | (m) | (m) |
| 2015-12-31 | $-14.79M | (m) | (m) | $11.83M | (m) | (m) |
| 2015-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-12-31 | $-9.32M | (m) | (m) | $7.46M | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |